New drug HS-20110 enters human testing for Hard-to-Treat cancers
NCT ID NCT06892379
First seen Feb 20, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This early-stage trial is testing a new drug called HS-20110 in 475 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Participants receive HS-20110 by IV infusion in 21-day cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BRCR Medical Center INC
RECRUITINGTamarac, Florida, 33321, United States
Contact
-
Carolina BioOncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact Phone: •••-•••-••••
Contact
-
Fort Wayne Medical Oncology and Hematology
RECRUITINGFort Wayne, Indiana, 46804, United States
Contact
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
SUN YAT-SEN University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-20110
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if HS-20110 will effectively shrink tumors. Side effects are unknown and could be serious.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.